News
OCGN
1.140
-3.39%
-0.040
Weekly Report: what happened at OCGN last week (0826-0830)?
Weekly Report · 6d ago
2 Penny Stocks That Wall Street Believes Can Soar Around 292% to 442%
Barchart · 08/28 17:06
BUZZ-U.S. STOCKS ON THE MOVE-Chewy, Abercrombie & Fitch, Kohl's
Reuters · 08/28 13:26
BUZZ-Ocugen rises on completing patient dosing in early-stage gene therapy trial
Reuters · 08/28 12:43
OCUGEN ANNOUNCES COMPLETION OF DOSING IN SUBJECTS WITH STARGARDT DISEASE IN HIGH DOSE COHORT OF PHASE 1/2 GARDIAN CLINICAL TRIAL OF OCU410ST—A MODIFIER GENE THERAPY
Reuters · 08/28 10:30
Ocugen Receives Health Canada Approval To Initiate Phase 3 LiMeliGhT Trial For OCU400
NASDAQ · 08/26 11:32
Ocugen Gets Health Canada Approval for Phase 3 Trial of Gene Therapy for Retinitis Pigmentosa
Dow Jones · 08/26 11:30
Ocugen Receives Green Light from Health Canada for Phase 3 Trial of Gene Therapy for Retinitis Pigmentosa
Benzinga · 08/26 11:09
OCUGEN INC - OCU400 REMAINS ON TRACK FOR 2026 BLA AND MAA APPROVAL TARGETS.
Reuters · 08/26 11:02
Weekly Report: what happened at OCGN last week (0819-0823)?
Weekly Report · 08/26 10:25
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Barchart · 08/26 06:02
*Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against The Company's Officers And Directors Following Earnings Restatement And Possible Insider Trading >OCGN
Dow Jones · 08/20 13:00
Weekly Report: what happened at OCGN last week (0812-0816)?
Weekly Report · 08/19 10:17
Weekly Report: what happened at OCGN last week (0805-0809)?
Weekly Report · 08/12 10:19
Peering Into Ocugen's Recent Short Interest
Benzinga · 08/09 20:15
Ocugen (OCGN) Receives a Buy from Noble Financial
TipRanks · 08/09 13:28
Buy Rating on Ocugen: Strong Financials and Promising Clinical Progress
TipRanks · 08/09 11:16
OCUGEN, INC. QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024
Press release · 08/08 13:18
Ocugen GAAP EPS of -$0.04 beats by $0.01, revenue of $1.14M
Seeking Alpha · 08/08 10:51
OCUGEN INC: OCU400 REMAINS ON TRACK FOR 2026 BLA AND MAA APPROVAL TARGETS.
Reuters · 08/08 10:45
More
Webull provides a variety of real-time OCGN stock news. You can receive the latest news about Ocugen Inc through multiple platforms. This information may help you make smarter investment decisions.
About OCGN
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.